The Critical Challenge: Maintaining Particle Size During Scale-Up
The transition of Lipid Nanoparticles (LNPs) from a controlled laboratory environment to clinical-grade production is one of the most significant hurdles in modern drug delivery. While the industry has seen a surge in nucleic acid therapeutics, many promising candidates stall during the scale-up phase. The core challenge often lies in the physics of the molecule itself: as batch volumes increase, maintaining a consistent particle size distribution and high encapsulation efficiency becomes exponentially more difficult.
In the context of nanomedicines, even a slight deviation in the Polydispersity Index (PDI) can drastically alter the pharmacokinetic profile of the drug, leading to unpredictable biodistribution or reduced therapeutic efficacy. To achieve GMP nanomedicine success, developers must bridge the gap between “benchtop” success and the rigorous, reproducible requirements of a commercial-ready process.
The Science of Scale: Precision Microfluidics and Flow Manufacturing
The science of LNP scale-up centers on the mixing kinetics of the lipid and aqueous phases. Traditional batch mixing often fails at larger scales because it cannot provide the rapid, homogeneous mixing required to control nanoparticle nucleation.
To overcome this, Ardena utilizes advanced microfluidics scale-up technologies, specifically Impingement Jet Mixing (IJM) and flow manufacturing. By controlling the Total Flow Rate (TFR) and the Flow Rate Ratio (FRR), we ensure that the lipids and nucleic acids collide in a highly controlled environment, producing uniform particles every time.
The verification of these processes occurs in our specialized nanoparticle characterization labs, where we utilize high-resolution analytical tools to monitor critical quality attributes (CQAs):
- Dynamic Light Scattering (DLS): To assess mean particle size and PDI.
- Asymmetric Flow Field-Flow Fractionation (AF4): For detailed size distribution analysis in complex samples.
- Cryo-TEM: To visualize the internal structure and morphology of the LNPs.
Comparison: Lab Scale vs. GMP Manufacturing
| Parameter | Lab Scale (R&D) | GMP Manufacturing (Scale-up) |
| Batch Volume | µL to mL | mL to 300L+ |
| Mixing Method | Manual Pipetting / Vortexing | Automated Microfluidics / IJM |
| Purification | Dialysis | Tangential Flow Filtration (TFF) |
| Control Environment | Standard Lab Bench | Segregated GMP Cleanrooms |
| Regulatory Level | Non-regulated | ICH & GMP Compliant |
Export to Sheets
The Ardena Advantage: Integrated CDMO Expertise
At Ardena, we position ourselves as the specialist for “hard-to-make” drugs. Our integrated model is designed to eliminate the data gaps that typically occur when moving between different service providers.
The Ardena Advantage lies in our end-to-end capabilities. Our Nanomedicine Development team works in tandem with our Drug Product experts, ensuring that the process developed at the bench is inherently scalable for our GMP nanomedicine facilities. Furthermore, our ability to handle high-potency APIs (HPAPIs) under OEB-5 conditions allows us to formulate even the most sensitive and potent payloads, including mRNA, siRNA, and pDNA.
By leveraging our internal Solid State Research and analytical teams, we define the stability profile of your LNPs early, ensuring that the final product remains viable from the manufacturing suite to the clinical site.
Successfully scaling an LNP formulation requires a blend of precise engineering and deep analytical insight. Don’t let your molecule be hindered by the complexities of tech transfer.
